SIMPLY BETTER BRANDS CORP (SBBC.CA)
CA82888R1055 - Common Stock
We assign a fundamental rating of 2 out of 10 to SBBC. SBBC was compared to 39 industry peers in the Pharmaceuticals industry. SBBC has a bad profitability rating. Also its financial health evaluation is rather negative. SBBC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SBBC had negative earnings in the past year.
SBBC had a negative operating cash flow in the past year.
SBBC had negative earnings in each of the past 5 years.
SBBC had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of SBBC (-81.58%) is worse than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.58% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-72.22%
ROA(5y)-51.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SBBC's Gross Margin of 50.71% is fine compared to the rest of the industry. SBBC outperforms 72.22% of its industry peers.
In the last couple of years the Gross Margin of SBBC has declined.
The Profit Margin and Operating Margin are not available for SBBC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.42%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SBBC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SBBC has been increased compared to 1 year ago.
Compared to 5 years ago, SBBC has more shares outstanding
Compared to 1 year ago, SBBC has a worse debt to assets ratio.
2.2 Solvency
SBBC has an Altman-Z score of -1.94. This is a bad value and indicates that SBBC is not financially healthy and even has some risk of bankruptcy.
SBBC has a Altman-Z score (-1.94) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.94 |
ROIC/WACCN/A
WACC7.97%
2.3 Liquidity
SBBC has a Current Ratio of 0.70. This is a bad value and indicates that SBBC is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of SBBC (0.70) is worse than 77.78% of its industry peers.
SBBC has a Quick Ratio of 0.70. This is a bad value and indicates that SBBC is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of SBBC (0.39) is worse than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.7 | ||
| Quick Ratio | 0.39 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 28.05% over the past year.
SBBC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -37.71%.
The Revenue has been growing by 79.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)28.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%174.57%
Revenue 1Y (TTM)-37.71%
Revenue growth 3Y79.67%
Revenue growth 5YN/A
Sales Q2Q%-70.07%
3.2 Future
Based on estimates for the next years, SBBC will show a very strong growth in Earnings Per Share. The EPS will grow by 48.41% on average per year.
Based on estimates for the next years, SBBC will show a decrease in Revenue. The Revenue will decrease by -0.56% on average per year.
EPS Next Y86.49%
EPS Next 2Y48.41%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-38.52%
Revenue Next 2Y-0.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
SBBC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
SBBC is valuated reasonably with a Price/Forward Earnings ratio of 10.46.
94.44% of the companies in the same industry are more expensive than SBBC, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.27, SBBC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.46 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SBBC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SBBC's earnings are expected to grow with 48.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.41%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SBBC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SIMPLY BETTER BRANDS CORP
TSX-V:SBBC (9/23/2024, 7:00:00 PM)
0.59
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap55.27M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.46 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.58% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.71% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover3.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.7 | ||
| Quick Ratio | 0.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)28.05%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y86.49%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-37.71%
Revenue growth 3Y79.67%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y